3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Ovarian Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioblastoma
1
Bone Marrow Diseases
1
Advanced Solid Tumor
1
Adenocarcinoma of Lung
1
Interventions
fludarabine phosphate
43
Whole-Body Irradiation
36
Mycophenolic Acid
36
Peripheral Blood Stem Cell Transplantation
31
Cyclophosphamide
31
Tacrolimus
28
Busulfan
22
Antilymphocyte Serum
21
Cyclosporine
19
fludarabine
17
ruxolitinib
16
Melphalan
16
Methotrexate
15
Cytarabine
12
thymoglobulin
9
Sirolimus
9
Etoposide
9
Granulocyte Colony-Stimulating Factor
8
Filgrastim
8
Cyclosporins
8
Radiotherapy
7
Cord Blood Stem Cell Transplantation
7
Rituximab
6
Alemtuzumab
6
merphos
5
Stem Cell Transplantation
5
Flow Cytometry
5
Azacitidine
5
sargramostim
4
ponatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Myeloproliferative Disorders
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts